-
The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
On April 8, 2024, the signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held in Beijing between Excyte Biopharma Ltd. (hereinafter referred to as &q
2024/04/22 admin 4
-
NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration
NHL/ALL免疫治疗候选双抗药物YK012 I期临床试验完成首例受试者给药 2023年5月24日，益科思特（北京）医药科技发展有限公司开发的用于治疗复发/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012（CD3×CD19）I期临床研究在中国医学科学院肿瘤医院I期病房完成首例给药。当日上午9:40，YK012注射液通过微量注射泵及输注管路缓缓流入受试者体内，至给药后24h，受试者无
2023/06/07 admin 72
-
NHL/ALL immunotherapy candidate dual antibody drug YK012 has officially entered the phase I clinical trial phase
NHL/ALL免疫治疗候选双抗药物YK012 正式进入I期临床试验阶段2023年5月8日，益科思特（北京）医药科技发展有限公司开发的用于治疗复发性/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012（CD3×CD19）I期临床研究在京正式启动。5月9日，首例受试者顺利签署知情同意书。中国医学科学院肿瘤医院临床研究中心副院长、肿瘤内科主任石远凯教授（左2），益科思特（北京）医药科技发
2023/06/07 admin 20
-
Nature Major findings: lower affinity agonist antibody is more effective
Nature重大发现：较低亲和力激动型抗体疗效更优长期以来，研究人员将高亲和力作为筛选治疗性抗体的关键标准。目前研究中的激动型抗体多数具有很高的亲和力，并且通过抗体的Fc功能进行交联，从而激活免疫细胞，但是这些抗体在临床中的疗效甚微，或具有较强的免疫不良反应。近日，Nature期刊上发表了题为“Reducing affinity as a strategy to boost immunomodul
2023/03/02 admin 24
-
Phase I clinical trial project of YK012 for injection was officially launched
After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.YK012 for injection is a new generation of safe, high-yield, long-acting and low-c
2023/02/07 admin 54
-
The 2022 year-end summary meeting ended successfully
On January 18, 2023, the 2022 year-end summary meeting of Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. was held in the A101 conference room. All members of the company and the cha
2023/01/10 admin 18
